States triple cartel claims against generic pharma

States pursuing claims of price fixing in the generic pharmaceutical industry asked a federal judge on Tuesday if they could amend the complaint to include 12 additional companies, 13 additional drugs and two senior executives to the list of defendants.

Get unlimited access to all Global Competition Review content